These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35251000)

  • 1. Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma.
    Liu R; Liang W; Hua Q; Wu L; Wang X; Li Q; Zhong F; Li B; Qiu Z
    Front Immunol; 2022; 13():819515. PubMed ID: 35251000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
    Wang Z; Wang C; Lin S; Yu X
    Front Oncol; 2021; 11():725292. PubMed ID: 34513703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
    Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
    Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
    Lin A; Gu T; Hu X; Zhang J; Luo P
    J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.
    Chen L; Zhou Q; Liu J; Zhang W
    Front Immunol; 2021; 12():759565. PubMed ID: 34777372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and validation of an immune-based prognostic score model in glioblastoma.
    Qin Z; Zhang X; Chen Z; Liu N
    Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Lin A; Zhang H; Meng H; Deng Z; Gu T; Luo P; Zhang J
    Front Immunol; 2021; 12():667875. PubMed ID: 34603277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetraspanins predict the prognosis and characterize the tumor immune microenvironment of glioblastoma.
    Li YC; Wu Y; Chen G; Zhu LZ; Luo X; Nie QQ; Zhang L; Zuo CJ
    Sci Rep; 2023 Aug; 13(1):13317. PubMed ID: 37587203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma.
    Zhang H; Hong Y; Wu T; Ben E; Li S; Hu L; Xie T
    Front Immunol; 2024; 15():1401967. PubMed ID: 38915399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches.
    Lofiego MF; Piazzini F; Caruso FP; Marzani F; Solmonese L; Bello E; Celesti F; Costa MC; Noviello T; Mortarini R; Anichini A; Ceccarelli M; Coral S; Di Giacomo AM; Maio M; Covre A;
    J Transl Med; 2024 Mar; 22(1):223. PubMed ID: 38429759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of an inflammatory response-related prognostic model and immune infiltration analysis in glioblastoma.
    Zhu W; Luo N; Li Q; Chen X; Li X; Fu M; Yang F; Chen Z; Zhang Y; Zhang Y; Peng X; Hu G
    Ann Transl Med; 2023 Jan; 11(2):69. PubMed ID: 36819551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
    Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.
    Niu Y; Lin A; Luo P; Zhu W; Wei T; Tang R; Guo L; Zhang J
    Front Pharmacol; 2020; 11():1213. PubMed ID: 32903385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of INSRR as an immune-related gene in the tumor microenvironment of glioblastoma by integrated bioinformatics analysis.
    Zhang H; Bao M; Liao D; Zhang Z; Tian Z; Yang E; Luo P; Jiang X
    Med Oncol; 2023 Apr; 40(6):161. PubMed ID: 37099121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
    Zhang N; Wei L; Ye M; Kang C; You H
    Front Immunol; 2020; 11():592612. PubMed ID: 33329578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Analysis of the Tumor Immune Microenvironment Landscape in Glioblastoma Reveals Tumor Heterogeneity and Implications for Prognosis and Immunotherapy.
    Zhao R; Pan Z; Li B; Zhao S; Zhang S; Qi Y; Qiu J; Gao Z; Fan Y; Guo Q; Qiu W; Wang S; Wang Q; Zhang P; Guo X; Deng L; Xue H; Li G
    Front Immunol; 2022; 13():820673. PubMed ID: 35309323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.